© 2004 by Oxford University Press
© 2004 Oxford University Press
CORRESPONDENCE |
Re: Have We Resolved How To Triage Equivocal Cervical Cytology?
Affiliations of authors: European Network for Cervical Cancer Screening, Co-ordinator Evaluation of New Technologies and Unit of Cancer Screening, Scientific Institute of Public Health, Brussels, Belgium (MA); Department of Medical Microbiology, Lund University, Malmö University Hospital, Malmö, Sweden (JD); Department of Clinical and Epidemiological Virology, University of Leuven, Leuven, Belgium (MVR); Centre for Evidence-Based Medicine, Belgian Branch of the Cochrane Collaboration, Department of General Practice, University of Leuven, Leuven, Belgium, and University of Maastricht, Maastricht, The Netherlands (FB); Central Lancashire Teaching Hospitals, Preston, U.K. (PM-H); Department of Obstetrics and Gynaecology, University Hospital of Ioannina, Ioannina, Greece (EP)
Correspondence to: Marc Arbyn, Scientific Institute of Public Health, J. Wytsmanstreet 14, B1050 Brussels, Belgium (e-mail: marc.arbyn@iph.fgov.be)
| The first 10% of the full text of this article appears below. |
In their recent editorial, Solomon and Schiffman (1) commented on our meta-analysis of the accuracy of the human papillomavirus (HPV) DNA testing as an alternative to a repeat Pap smear to triage women with equivocal cervical cytology (2). In general, they agreed with our conclusion that detection of high-risk HPV DNA using the Hybrid Capture 2 (HC2) assay (Digene, Gaithersburg, MD) predicts the presence
Response to this Correspondence
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2004 96: 1402.